Why Heron Therapeutics Stock Soared Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares end Monday higher by a healthy 26.9%. The catalyst?
Heron's stock bolted northward in response to two late-stage readouts for its non-opioid pain medication, HTX-011, in patients undergoing bunionectomy (a type of bunion surgery) and hernia repair, respectively.
Digging into the details, HTX-011 reportedly generated statistically significant reductions in both pain intensity and opioid use through a 72-hour period following surgery, compared to patients receiving either a placebo or bupivacaine solution.
If approved, Heron's experimental pain medication is expected to compete directly against Pacira Pharmaceuticals' (NASDAQ: PCRX) FDA-approved Exparel, a liposomal formulation of bupivacaine. Last year, Pacira's drug hauled in a noteworthy $280 million in sales.
Heron is on track to file a New Drug Application for HTX-011 in the second half of this year. While HTX-011's commercial opportunity as a competitor to Exparel is substantial, the drug's ability to reduce opioid use in the postoperative setting could open up a far larger market.
If the FDA grants HTX-011 a broad label in the postoperative setting, for instance, the drug should be able to easily surpass Exparel's commercial trajectory and perhaps even go on to become a blockbuster-level product (sales in excess of $1 billion per year).
Having said that, Heron is still in the process of learning how to effectively market drugs, so an approval doesn't necessarily mean that HTX-011 will get off to a roaring start. In fact, the company would probably be better off putting itself up for sale in the event HTX-011 does get a green light from the FDA early next year.
10 stocks we like better than Heron TherapeuticsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Heron Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.